Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China
|
MSCI China Small-Cap
|
Hang Seng Index
|
Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
    • China ESG Focus
  • Fast News
  • Expert Corner
  • Audio/Video
  • IPO
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

Sinopharm

BRIEF: Sinopharm’s revenue and profit rise, but cash outflow continues in first quarter

Drug wholesaler and retailer Sinopharm Group Co. Ltd. (1099.HK; 600511.SH) on Wednesday reported its revenue increased 6.6% year-over-year to 13.56 billion yuan ($1.99 billion) in the first quarter, while its…
April 23, 2026
1099.HK
600511.SHG
Falling gross margins; Good Doctor Cloud Healthcare's business lacks highlights

Good Doctor Cloud Healthcare’s ailing margins belie uninspired new listing

The supplier of services for primary healthcare providers has applied for a Hong Kong IPO, reporting strong profit growth last year on non-operational factors Key Takeaways: Good Doctor Cloud Healthcare…
April 20, 2026

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

Drugmaker CSPC Pharma gets the green light to produce China’s first homegrown mRNA vaccine, but the breakthrough comes too late in the pandemic to impress investors Key Takeaways: News of…
March 29, 2023
1093.HK

YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs

The drug distributor for pharmacies and community-level medical institutions has filed for a Hong Kong listing, boasting strong revenue growth but also massive losses Key Takeaways: YSB has filed for…
May 31, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
May 26, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
April 18, 2022
B.US

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

Global agreement for oral anti-viral comes just months after company signed separate similar tie-up for a Covid mRNA vaccine also in development Key Takeaways Everest has signed a global licensing…
January 20, 2022
Load more

Recent Articles

April 23, 2026

BRIEF: Sinopharm’s revenue and profit rise, but cash outflow continues in first quarter

1099.HK
600511.SHG
April 20, 2026

Good Doctor Cloud Healthcare’s ailing margins belie uninspired new listing

March 29, 2023

CSPC Pharma wins China’s mRNA vaccine race, but just not fast enough

1093.HK
May 31, 2022

YSB’s B2B Pharma Platform: Sexier Than the SOEs, But Stodgier Than B2Cs

May 26, 2022

CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?

April 18, 2022

AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

B.US
January 20, 2022

Everest Boosts Covid Bet With New Licensing Deal Despite Crowded Field

RELATED ARTICLES

  1. Jacobio Pharma turn profit
    March 19, 2026
    Jacobio Pharma poised to turn a profit from precision cancer drugs
    1167.HK
  2. March 31, 2026
    BRIEF: Lens Technology’s profit, revenue rise as robotics business accelerates
    6613.HK
    300433.SHE
  3. January 2, 2026
    Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
  4. December 5, 2025
    Waterdrop splashes back to revenue growth. But are investors listening?
    WDH.US
  5. March 11, 2026
    BRIEF: Impro Precision revenue, profit rise to record highs on AI boom
    1286.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2026 Bamboo Works. All rights reserved.